Pfizer Inc

NYSE: PFE
$24.94
+$0.14 (+0.5%)
Real Time Data Delayed 15 Min.

PFE Articles

Reuters:   The GM board pushed out CEO Henderson. Reuters:   Bernanke will defend the Fed’s record and his before Congress. Reuters:   China will let foreigners set up limited partnerships....
Reuters:   Markets hit their 2009 highs. Reuters:   Dodd is set to unveil his financial reform bill which calls for merging many bank regulators. Reuters:   Kraft’s (NYSE:KFT) bid for Cadbury...
Updated throughout the day. Updated 1.05 PM EST:  Las Vagas Sands (NYSE:LVS) will try to raise $2.5 billion though an IPO in Hong Kong  (AP) Updated 11.12 AM EST: Pfizer (NYSE:PFE) is considering a...
Reuters:   Investors in the banking sector were disturbed by the CIT (NYSE:CIT) bankruptcy. Reuters:   Summers will lead a high level meeting on the economy. Reuters:   US companies are holding...
We have seen the earnings reports from all five DJIA components which were on deck to report this Tuesday.  We are seeing a theme here: almost all posted lower earnings from a year ago that still...
Pfizer (NYSE:PFE) had a better quarter than many expected. The drug company reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3%. EPS fell to $.51 from...
We have provided some basic details on Tuesday’s earnings reports from DJIA components Caterpillar Inc. (NYSE: CAT), DuPont or EI DuPont de Nemours & Co. (NYSE: DD), Pfizer Inc. (NYSE: PFE),...
We are starting to see some elevated options trading that appeared on the unusual volume screens.  Many of these are pre-earnings trading and some are on other expectations.  We have more detailed...
The short interest in Apple (NASDAQ:AAPL) was steady in the period that ended on September 30 at 16 million shares.The bet being made against RIM (NASDAQ:RIMM) rose 13% to 13% to 19.2 million.  The...
Reuters:   The sell-off in Chinese stocks may be overdone based on earnings. Reuters:   A report blamed the SEC for not doing its job investigating Madoff. Reuters:   The Fed says the risks to...
Now that we are out of the woods in the crash scenario, assuming this week is no ill omen, investors may want to know which of the big companies would start to deploy their billions and billions of...
Fidelity Management & Research Company, or FMR, was among the giants which released its quarterly holdings over the most recent days.  While it is always interesting to see which holdings are...
Diabetes is becoming an epidemic in the U.S. and the Western World.  The ties to obesity are often direct, so the potential treatments are often directly tied as well.  We did a recent dig down for...
MannKind Corporation (NASDAQ: MNKD) is getting hit after the company announced that it priced a secondary offering of 7,400,000 shares of its common stock.  While the press release does not say what...
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market....